Cargando…

Antimicrobial resistance of Neisseria gonorrhoeae in Germany: low levels of cephalosporin resistance, but high azithromycin resistance

BACKGROUND: The widespread antimicrobial resistance of Neisseria gonorrhoeae is a serious problem for the treatment and control of gonorrhoea. Many of the previously effective therapeutic agents are no longer viable. Because N. gonorrhoeae infections are not reportable in Germany, only limited data...

Descripción completa

Detalles Bibliográficos
Autores principales: Buder, Susanne, Dudareva, Sandra, Jansen, Klaus, Loenenbach, Anna, Nikisins, Sergejs, Sailer, Andrea, Guhl, Eva, Kohl, Peter K., Bremer, Viviane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772720/
https://www.ncbi.nlm.nih.gov/pubmed/29343220
http://dx.doi.org/10.1186/s12879-018-2944-9
_version_ 1783293456242704384
author Buder, Susanne
Dudareva, Sandra
Jansen, Klaus
Loenenbach, Anna
Nikisins, Sergejs
Sailer, Andrea
Guhl, Eva
Kohl, Peter K.
Bremer, Viviane
author_facet Buder, Susanne
Dudareva, Sandra
Jansen, Klaus
Loenenbach, Anna
Nikisins, Sergejs
Sailer, Andrea
Guhl, Eva
Kohl, Peter K.
Bremer, Viviane
author_sort Buder, Susanne
collection PubMed
description BACKGROUND: The widespread antimicrobial resistance of Neisseria gonorrhoeae is a serious problem for the treatment and control of gonorrhoea. Many of the previously effective therapeutic agents are no longer viable. Because N. gonorrhoeae infections are not reportable in Germany, only limited data on disease epidemiology and antimicrobial susceptibility patterns are available. The Gonococcal Resistance Network (GORENET) is a surveillance project to monitor trends in the antimicrobial susceptibility of N. gonorrhoeae in Germany in order to guide treatment algorithms and target future prevention strategies. METHODS: Between April 2014 and December 2015, data on patient-related information were collected from laboratories nationwide, and susceptibility testing was performed on 537 N. gonorrhoeae isolates forwarded from the network laboratories to the Conciliar Laboratory for gonococci. Susceptibility results for cefixime, ceftriaxone, azithromycin, ciprofloxacin and penicillin were defined according to EUCAST 4.0 standards. Percentages, medians and interquartile ranges (IQR) were calculated. RESULTS: Altogether, 90% of isolates were from men. The median age was 32 (IQR 25–44) years for men and 25 (IQR 22–40) years for women (p-value < 0.001). The most frequently tested materials among men were urethral (96.1%) and rectal swabs (1.7%), and among women, it was mainly endocervical and vaginal swabs (84.3%). None of the isolates were resistant to ceftriaxone. Furthermore, 1.9% (in 2014) and 1.4% (in 2015) of the isolates were resistant to cefixime, 11.9% and 9.8% showed resistance against azithromycin, 72.0% and 58.3% were resistant to ciprofloxacin, and 29.1% and 18.8% were resistant to penicillin. CONCLUSIONS: Resistance to ceftriaxone was not detected, and the percentage of isolates with resistance to cefixime was low, whereas azithromycin resistance showed high levels during the observation period. The rates of ciprofloxacin resistance and penicillin resistance were very high across Germany. Continued surveillance of antimicrobial drug susceptibilities for N. gonorrhoeae remains highly important to ensure efficient disease management.
format Online
Article
Text
id pubmed-5772720
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57727202018-01-26 Antimicrobial resistance of Neisseria gonorrhoeae in Germany: low levels of cephalosporin resistance, but high azithromycin resistance Buder, Susanne Dudareva, Sandra Jansen, Klaus Loenenbach, Anna Nikisins, Sergejs Sailer, Andrea Guhl, Eva Kohl, Peter K. Bremer, Viviane BMC Infect Dis Research Article BACKGROUND: The widespread antimicrobial resistance of Neisseria gonorrhoeae is a serious problem for the treatment and control of gonorrhoea. Many of the previously effective therapeutic agents are no longer viable. Because N. gonorrhoeae infections are not reportable in Germany, only limited data on disease epidemiology and antimicrobial susceptibility patterns are available. The Gonococcal Resistance Network (GORENET) is a surveillance project to monitor trends in the antimicrobial susceptibility of N. gonorrhoeae in Germany in order to guide treatment algorithms and target future prevention strategies. METHODS: Between April 2014 and December 2015, data on patient-related information were collected from laboratories nationwide, and susceptibility testing was performed on 537 N. gonorrhoeae isolates forwarded from the network laboratories to the Conciliar Laboratory for gonococci. Susceptibility results for cefixime, ceftriaxone, azithromycin, ciprofloxacin and penicillin were defined according to EUCAST 4.0 standards. Percentages, medians and interquartile ranges (IQR) were calculated. RESULTS: Altogether, 90% of isolates were from men. The median age was 32 (IQR 25–44) years for men and 25 (IQR 22–40) years for women (p-value < 0.001). The most frequently tested materials among men were urethral (96.1%) and rectal swabs (1.7%), and among women, it was mainly endocervical and vaginal swabs (84.3%). None of the isolates were resistant to ceftriaxone. Furthermore, 1.9% (in 2014) and 1.4% (in 2015) of the isolates were resistant to cefixime, 11.9% and 9.8% showed resistance against azithromycin, 72.0% and 58.3% were resistant to ciprofloxacin, and 29.1% and 18.8% were resistant to penicillin. CONCLUSIONS: Resistance to ceftriaxone was not detected, and the percentage of isolates with resistance to cefixime was low, whereas azithromycin resistance showed high levels during the observation period. The rates of ciprofloxacin resistance and penicillin resistance were very high across Germany. Continued surveillance of antimicrobial drug susceptibilities for N. gonorrhoeae remains highly important to ensure efficient disease management. BioMed Central 2018-01-17 /pmc/articles/PMC5772720/ /pubmed/29343220 http://dx.doi.org/10.1186/s12879-018-2944-9 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Buder, Susanne
Dudareva, Sandra
Jansen, Klaus
Loenenbach, Anna
Nikisins, Sergejs
Sailer, Andrea
Guhl, Eva
Kohl, Peter K.
Bremer, Viviane
Antimicrobial resistance of Neisseria gonorrhoeae in Germany: low levels of cephalosporin resistance, but high azithromycin resistance
title Antimicrobial resistance of Neisseria gonorrhoeae in Germany: low levels of cephalosporin resistance, but high azithromycin resistance
title_full Antimicrobial resistance of Neisseria gonorrhoeae in Germany: low levels of cephalosporin resistance, but high azithromycin resistance
title_fullStr Antimicrobial resistance of Neisseria gonorrhoeae in Germany: low levels of cephalosporin resistance, but high azithromycin resistance
title_full_unstemmed Antimicrobial resistance of Neisseria gonorrhoeae in Germany: low levels of cephalosporin resistance, but high azithromycin resistance
title_short Antimicrobial resistance of Neisseria gonorrhoeae in Germany: low levels of cephalosporin resistance, but high azithromycin resistance
title_sort antimicrobial resistance of neisseria gonorrhoeae in germany: low levels of cephalosporin resistance, but high azithromycin resistance
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772720/
https://www.ncbi.nlm.nih.gov/pubmed/29343220
http://dx.doi.org/10.1186/s12879-018-2944-9
work_keys_str_mv AT budersusanne antimicrobialresistanceofneisseriagonorrhoeaeingermanylowlevelsofcephalosporinresistancebuthighazithromycinresistance
AT dudarevasandra antimicrobialresistanceofneisseriagonorrhoeaeingermanylowlevelsofcephalosporinresistancebuthighazithromycinresistance
AT jansenklaus antimicrobialresistanceofneisseriagonorrhoeaeingermanylowlevelsofcephalosporinresistancebuthighazithromycinresistance
AT loenenbachanna antimicrobialresistanceofneisseriagonorrhoeaeingermanylowlevelsofcephalosporinresistancebuthighazithromycinresistance
AT nikisinssergejs antimicrobialresistanceofneisseriagonorrhoeaeingermanylowlevelsofcephalosporinresistancebuthighazithromycinresistance
AT sailerandrea antimicrobialresistanceofneisseriagonorrhoeaeingermanylowlevelsofcephalosporinresistancebuthighazithromycinresistance
AT guhleva antimicrobialresistanceofneisseriagonorrhoeaeingermanylowlevelsofcephalosporinresistancebuthighazithromycinresistance
AT kohlpeterk antimicrobialresistanceofneisseriagonorrhoeaeingermanylowlevelsofcephalosporinresistancebuthighazithromycinresistance
AT bremerviviane antimicrobialresistanceofneisseriagonorrhoeaeingermanylowlevelsofcephalosporinresistancebuthighazithromycinresistance
AT antimicrobialresistanceofneisseriagonorrhoeaeingermanylowlevelsofcephalosporinresistancebuthighazithromycinresistance